Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest news about X4 Pharmaceuticals aggregated by PharmaCompass.com.

    Client Virtual Booth

    X4 PHARMACEUTICALS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    X4 Pharmaceuticals
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    955 Massachusetts Avenue, 4th Floor Cambridge, MA 02139
    Telephone
    Telephone
    +(857) 529-8300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.x4pharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/x4-pharmaceuticals/?originalSubdomain=in
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    X4 enters commercial fold with FDA approval of rare disease drug Xolremdi
    X4 enters commercial fold with FDA approval of rare disease drug Xolremdi

    https://www.fiercepharma.com/pharma/x4-enters-commercial-fold-fda-approval-rare-disease-drug-xolremdi

    FIERCE PHARMA
    30 Apr 2024
    Share Share
    X4 Pharma's XOLREMDI™ Approved by FDA for WHIM Syndrome
    X4 Pharma's XOLREMDI™ Approved by FDA for WHIM Syndrome

    https://www.globenewswire.com/news-release/2024/04/29/2871050/0/en/X4-Pharmaceuticals-Announces-FDA-Approval-of-XOLREMDI-mavorixafor-Capsules-First-Drug-Indicated-in-Patients-with-WHIM-Syndrome.html

    GLOBENEWSWIRE
    29 Apr 2024
    Share Share
    PANTHERx® Rare Partnering with X4 for XOLREMDI™ Distribution
    PANTHERx® Rare Partnering with X4 for XOLREMDI™ Distribution

    https://www.prnewswire.com/news-releases/pantherx-rare-partnering-with-x4-pharmaceuticals-inc-for-the-distribution-of-xolremdi-mavorixafor-the-first-fda-approved-therapy-indicated-for-use-in-patients-with-whim-syndrome-302130332.html

    PR NEWSWIRE
    29 Apr 2024
    Share Share
    X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com/news-release/2024/04/02/2856457/0/en/X4-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    02 Apr 2024
    Share Share
    X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
    X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

    https://www.globenewswire.com/news-release/2024/04/01/2855122/0/en/X4-Pharmaceuticals-to-Participate-in-Upcoming-April-Investor-Conferences.html

    GLOBENEWSWIRE
    01 Apr 2024
    Share Share
    X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results
    X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results

    https://www.globenewswire.com/news-release/2024/03/21/2850047/0/en/X4-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    21 Mar 2024
    Share Share
    X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results
    X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results

    https://www.globenewswire.com//news-release/2024/03/12/2844468/0/en/X4-Pharmaceuticals-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Host-a-Conference-Call-and-Webcast-on-March-21-2024.html

    GLOBENEWSWIRE
    12 Mar 2024
    Share Share
    X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com//news-release/2024/03/01/2839064/0/en/X4-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    01 Mar 2024
    Share Share
    X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    X4 Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    https://www.globenewswire.com//news-release/2024/02/01/2822437/0/en/X4-Pharmaceuticals-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    01 Feb 2024
    Share Share
    X4 Pharma Announces Presentation of Data from Mavorixafor Phase 2 Trial
    X4 Pharma Announces Presentation of Data from Mavorixafor Phase 2 Trial

    https://www.globenewswire.com//news-release/2023/12/09/2793437/0/en/X4-Pharmaceuticals-Announces-Presentation-of-Additional-Data-from-Mavorixafor-Phase-2-Trial-in-Chronic-Neutropenia-at-ASH-2023.html

    GLOBENEWSWIRE
    09 Dec 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search